Zobrazeno 1 - 10
of 58 802
pro vyhledávání: '"Phase Ib"'
Autor:
Alcantara, Marion1,2 (AUTHOR), Chevrier, Marion3 (AUTHOR), Jardin, Fabrice4 (AUTHOR), Schmitt, Anna5 (AUTHOR), Houillier, Caroline6 (AUTHOR), Oberic, Lucie7 (AUTHOR), Chinot, Olivier8 (AUTHOR), Morschhauser, Franck9 (AUTHOR), Peyrade, Frédéric10 (AUTHOR), Houot, Roch11 (AUTHOR), Hoang-Xuan, Khê6 (AUTHOR), Ghesquieres, Hervé12 (AUTHOR), Soussain, Carole2,13 (AUTHOR) carole.soussain@curie.fr
Publikováno v:
Journal of Hematology & Oncology. 10/19/2024, Vol. 17 Issue 1, p1-13. 13p.
Autor:
Yin, Lina1 (AUTHOR), Jiang, Wei1 (AUTHOR), Liu, Shuai2 (AUTHOR), Fu, Yi3 (AUTHOR), Zhou, Lin1 (AUTHOR), Pei, Xuan1 (AUTHOR), Ye, Shuang1 (AUTHOR), Shen, Wenbin1 (AUTHOR), Yang, Huijuan1 (AUTHOR) huijuanyang@hotmail.com, Shan, Boer1 (AUTHOR) shanboer@126.com
Publikováno v:
BMC Medicine. 10/29/2024, Vol. 22 Issue 1, p1-12. 12p.
Autor:
Lina Yin, Wei Jiang, Shuai Liu, Yi Fu, Lin Zhou, Xuan Pei, Shuang Ye, Wenbin Shen, Huijuan Yang, Boer Shan
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Neoadjuvant chemotherapy may be considered for patients with ovarian cancer (OC) whose tumors are deemed unlikely to be completely cytoreduced to no gross residual disease (R0) or who are poor surgical candidates. This Ib/II study
Externí odkaz:
https://doaj.org/article/b1f4c536d6d54eba85e05685b2d3d915
Autor:
Koo, Dong-Hoe1 (AUTHOR), Jung, Minkyu2 (AUTHOR), Kim, Yeul Hong3 (AUTHOR), Jeung, Hei-Cheul4 (AUTHOR), Zang, Dae Young5 (AUTHOR), Bae, Woo Kyun6 (AUTHOR), Kim, Hyunki7 (AUTHOR), Kim, Hyo Song2 (AUTHOR), Lee, Choong-kun2 (AUTHOR), Kwon, Woo Sun8 (AUTHOR), Chung, Hyun Cheol2 (AUTHOR), Rha, Sun Young2,8,9 (AUTHOR) rha7655@yuhs.ac
Publikováno v:
Cancer Research & Treatment. Oct2024, Vol. 56 Issue 4, p1136-1145. 10p.
Autor:
Marion, Alcantara1,2 (AUTHOR), Marion, Chevrier3 (AUTHOR), Fabrice, Jardin4 (AUTHOR), Anna, Schmitt5 (AUTHOR), Caroline, Houillier6 (AUTHOR), Lucie, Oberic7 (AUTHOR), Olivier, Chinot8 (AUTHOR), Franck, Morschhauser9 (AUTHOR), Frédéric, Peyrade10 (AUTHOR), Roch, Houot11 (AUTHOR), Khê, Hoang-Xuan6 (AUTHOR), Hervé, Ghesquieres12 (AUTHOR), Carole, Soussain2,13 (AUTHOR) carole.soussain@curie.fr
Publikováno v:
Journal of Hematology & Oncology. 9/19/2024, Vol. 17 Issue 1, p1-13. 13p.
Autor:
Li, Jin1,2 (AUTHOR), Liu, Jihong3 (AUTHOR), Yin, Rutie4 (AUTHOR), Zou, Dongling5 (AUTHOR), Zheng, Hong6 (AUTHOR), Cao, Junning2,7 (AUTHOR), Chen, Zhendong8 (AUTHOR), Sun, Wei9 (AUTHOR), Gao, Yunong6 (AUTHOR), Zhang, Songling10 (AUTHOR), Zeng, Linjuan11 (AUTHOR), An, Ruifang12 (AUTHOR), Lu, Xianping13 (AUTHOR), Ye, Shuang1,2 (AUTHOR), Wu, Xiaohua1,2 (AUTHOR) docwuxh@hotmail.com
Publikováno v:
Molecular Cancer. 8/9/2024, Vol. 23 Issue 1, p1-8. 8p.
Autor:
Ahmed, Jibran1, Stephen, Bettzy1, Yali Yang1, Kwiatkowski, Evan1, Ejezie, Chinenye Lynette1, Pant, Shubham1 SPant@mdanderson.org
Publikováno v:
Journal of Immunotherapy & Precision Oncology. May2024, Vol. 7 Issue 2, p73-81. 9p.
Autor:
Ming Bai1, Yao Lu1, Chunmei Shi2, Jianwei Yang3, Wei Li4, Xianli Yin5, Chenghui Huang6, Lin Shen7, Liangzhi Xie8, Yi Ba1,9 bayi@tjmuch.com
Publikováno v:
Cancer Biology & Medicine. Jul2024, Vol. 21 Issue 7, p636-650. 15p.
Autor:
Ke Cheng, Xiaoying Li, Wanrui Lv, Gang Zhao, Ruihan Zhou, Chen Chang, Heqi Yang, Ruizhen Li, Zhiping Li, Ye Chen, Cheng Yi, Ouying Yan, Chaoxin Xiao, Yi Zhang, Junjie Xiong, Zixin Huang, Weikang Shao, Xin You, Wenhao Guo, Du He, Wenwu Ling, Rui Wang, Bole Tian, Chengjian Zhao, Dan Cao
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Advanced pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Immunotherapy alone offers limited efficacy, but it is still unknown whether its combination with chemotherapy could offer synergistic anti-tumor effects. This phase Ib
Externí odkaz:
https://doaj.org/article/e145a71d470e4c01a49790648824e171
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial
Autor:
Jiayong Liu, Xuan Wang, Zhongwu Li, Shunyu Gao, Lili Mao, Jie Dai, Caili Li, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Yumei Lai, Zhichao Tan, Bin Lian, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Juan Li, Jun Guo, Lu Si
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Neoadjuvant PD-1 inhibitor is promising in cutaneous melanoma but remains unknown in acral melanoma (AM). This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic
Externí odkaz:
https://doaj.org/article/2aa1d96381b94974aba9adba421e3280